DRI Capital

About

DRI is a pioneer and global leader in healthcare royalty monetization with a 32-year history of collaboration with leading biotech and pharmaceutical companies, hospitals, universities and inventors. Between 2006 and 2018, DRI Capital, through three managed funds, acquired over 60 separate royalty streams for an aggregate value of over $2 billion on some of the world’s best-selling pharmaceutical products. In 2021 DRI transitioned from a managed fund to a public company structure, through the listing of DRI Healthcare Trust on the Toronto Stock Exchange which subsequently acquired the royalty assets from its managed funds. DRI Healthcare Trust’s mandate is to grow its royalty portfolio and resulting cash flows through a focused acquisition program utilizing the experience and proprietary assets of the DRI team.

Source: DRI Capital

Strategy

At DRI Capital we focus on uncovering attractive investment opportunities that deliver long-term value. We take pride in our ability to complete transactions quickly, efficiently and on mutually beneficial terms.

TARGET FOCUS -

MEDICALLY NECESSARY THERAPEUTICS
Products that exhibit a safe and efficacious profile and are medically necessary for patients to improve their health or quality of life, delivering a meaningful impact to the patient population. These products are typically used to treat chronic, critical or rare diseases.

STRONG INTELLECTUAL PROPERTY PROTECTION
Products with strong patent and/or regulatory protection and focus on products protected from generic or biosimilar competition.

MARKET LEADING PRODUCTS
Products that are market leaders in their therapeutic area, with commercial track record and strong growth potential.

LEADING MARKETERS
Products that are sold by high quality marketers. This includes large pharmaceutical and biotechnology companies and companies with a particular expertise in a specific, relevant segment of the pharmaceutical industry or therapeutic area.



UNIQUE APPROACH-

RELATIONSHIP FOCUSED
We take the time to build relationships with potential partners including individual inventors, academic and research institutions and life sciences companies. In so doing, we complete transactions tailored to each royalty recipient’s unique needs and circumstances.

PROPRIETARY DATABASE
Over our 32-year history, DRI has built and maintained a proprietary database of over 6,500 royalties on over 2,000 products that gives us significant market intelligence in identifying royalties to add to our portfolio and the inventors and institutions that own them.

EXPERIENCE AND EXPERTISE
Collectively, our professional team has over 150 years of combined experience. The team holds deep life sciences industry expertise drawn from a variety of disciplines including pharmaceutical, scientific, financial, healthcare, intellectual property and legal backgrounds. The breadth and depth of our team allows us to identify unique attractive opportunities for growth and conduct comprehensive due diligence on such investments.

FLEXIBLE APPROACH
Products that are sold by high quality marketers. This includes large pharmaceutical and biotechnology companies and companies with a particular expertise in a specific, relevant segment of the pharmaceutical industry or therapeutic area.

PROVEN TRACK RECORD
Throughout our history, DRI has developed a sterling reputation with royalty sellers through our proven capability to execute on transactions, and with investors due to our ability to identify attractive opportunities to acquire assets accretively.

Source: DRI Capital